Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Blood (2022) 140 (Supplement 1): 222–223.

https://doi.org/10.1182/blood-2022-166700

Published: 2022

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Blood (2020) 135 (6): 411–428.

https://doi.org/10.1182/blood.2019001262

Published: 2020

Includes: Supplemental data

Journal Articles

Minimal residual disease is an independent predictor for 10-year survival in CLL

Marwan Kwok, Andy C. Rawstron, Abraham Varghese, Paul A. S. Evans, Sheila J. M. O’Connor, Chi Doughty, Darren J. Newton, Paul Moreton, Peter Hillmen

Blood (2016) 128 (24): 2770–2773.

https://doi.org/10.1182/blood-2016-05-714162

Published: 2016

Includes: Supplemental data

Journal Articles

Validation of Plasma Cell Immunophenotype As a Biomarker to Identify High-Risk Smoldering Myeloma

Andy C Rawstron, BSc, PhD, Alex Smith, Ruth Mary de Tute, PhD FRCPath, Dan Painter, Eve Roman, Roger G Owen, MD

Blood (2016) 128 (22): 4451.

https://doi.org/10.1182/blood.V128.22.4451.4451

Published: 2016

Journal Articles

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Andy C Rawstron, BSc, PhD, Talha Munir, Samuel Muñoz-Vicente, Kristian Brock, MSc, BSc, Francesca J Yates, PhD MSci, Rebecca Bishop, BSc, Surita Dalal, Ruth Mary de Tute, PhD FRCPath, Adrian Bloor, Oonagh M Sheehy, MB BSc FRCP FRCPAth, Andrew R. Pettitt, Christopher P Fox, MBChB, MRCP, FRCPath, Christopher Fegan, Stephen Devereux, PhD FRCP, FRCPath, Donald Macdonald, Peter Hillmen

Blood (2016) 128 (22): 2049.

https://doi.org/10.1182/blood.V128.22.2049.2049

Published: 2016

Journal Articles

Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World

Alexandra G Smith, PhD, Timothy Bagguley, MSc, Eve Roman, PhD, Andy C Rawstron, James R Bailey, MA MBBS MRCP, Debra Howell, PhD, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Burton Cathy, Gordon Cook, MD PhD, Russell Patmore, MRCP FRCPath

Blood (2016) 128 (22): 3546.

https://doi.org/10.1182/blood.V128.22.3546.3546

Published: 2016

Journal Articles

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Ruth Mary de Tute, PhD FRCPath, Andy C Rawstron, BSc, PhD, David A Cairns, MSc, PhD, Charlotte Pawlyn, MB BChir, Faith E Davies, MD, Corinne Collett, Martin F Kaiser, John R Jones, MD, Anna Waterhouse, Alina Striha, MSc, Gordon Cook, MDPhD, Matthew W Jenner, MD, Nigel H Russell, MD, Mark T Drayson, MD PhD, Walter M Gregory, PhD, Graham H Jackson, MD PhD, Gareth J Morgan, MD PhD, Roger G Owen, MD

Blood (2016) 128 (22): 245.

https://doi.org/10.1182/blood.V128.22.245.245

Published: 2016

Journal Articles

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

Andy C Rawstron, BSc, PhD, Dena Howard, Lucy McParland, Ruth Mary de Tute, PhD FRCPath, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, PhD, Rebecca Bishop, BSc, Francesca J Yates, PhD MSci, Kristian Brock, MSc, BSc, Samuel Muñoz-Vicente, Peter Hillmen

Blood (2016) 128 (22): 3226.

https://doi.org/10.1182/blood.V128.22.3226.3226

Published: 2016

Journal Articles

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Ruth Mary de Tute, PhD FRCPath, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Christopher T Manbridge, Josh Caddy, Keith Pugh, PhD, Peter W.M. Johnson, FRCP, Andrew J Davies, MRCP, Andrew Jack, PhD MB

Blood (2015) 126 (23): 2669.

https://doi.org/10.1182/blood.V126.23.2669.2669

Published: 2015

Journal Articles

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

Blood (2015) 126 (23): 4146.

https://doi.org/10.1182/blood.V126.23.4146.4146

Published: 2015

Journal Articles

The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring

Andy C Rawstron, Dena Cohen, Ruth Mary De Tute, Lucy McParland, Laura Collett, David Phillips, Anna Chalmers, Abraham Mullasseril Varghese, Talha Munir, Walter M Gregory, Peter Hillmen

Blood (2015) 126 (23): 1717.

https://doi.org/10.1182/blood.V126.23.1717.1717

Published: 2015

Journal Articles

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Andy C. Rawstron, Walter M. Gregory, Ruth M. de Tute, Faith E. Davies, Sue E. Bell, Mark T. Drayson, Gordon Cook, Graham H. Jackson, Gareth J. Morgan, J. Anthony Child, Roger G. Owen

Blood (2015) 125 (12): 1932–1935.

https://doi.org/10.1182/blood-2014-07-590166

Published: 2015

Includes: Supplemental data

Journal Articles

Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction

Andy C Rawstron, BSc, PhD, Walter Gregory, PhD, Ruth M de Tute, Faith E Davies, MD, Susan E Bell, DPhil, Mark T Drayson, MDPhD, Gordon Cook, MD, Graham H Jackson, MD, James A Child, Gareth J. Morgan, MD PhD, Roger G Owen

Blood (2014) 124 (21): 3416.

https://doi.org/10.1182/blood.V124.21.3416.3416

Published: 2014

Journal Articles

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Ruth M de Tute, MSc, Jane Shingles, PhD, Andy C. Rawstron, PhD, Roger G Owen, MD

Blood (2014) 124 (21): 3425.

https://doi.org/10.1182/blood.V124.21.3425.3425

Published: 2014

Journal Articles

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Quentin A. Hill, Andy C. Rawstron, Ruth M. de Tute, Roger G. Owen

Blood (2014) 124 (8): 1296–1299.

https://doi.org/10.1182/blood-2014-04-566521

Published: 2014

Journal Articles

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Ruth M de Tute, MSc, Sharon Barrans, PhD, Andy C. Rawstron, PhD, Peter W.M. Johnson, MD, FRCP, Andrew J Davies, MRCP, PhD, Andrew Jack, PhD

Blood (2013) 122 (21): 3013.

https://doi.org/10.1182/blood.V122.21.3013.3013

Published: 2013

Journal Articles

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Peter Hillmen, MB ChB, PhD, Donald Milligan, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, Lucy McParland, Anna Chalmers, Tahla Munir, MB ChB, Abraham M Varghese, MB ChB, Andy C Rawstron, BSc, PhD, David J Allsup, MD, PhD, Scott Marshall, MD, Alex Smith, BSc, Corinne Collett, Walter Gregory, PhD, Andrew Duncombe, MD, Dena Cohen, BSc, MSc

Blood (2013) 122 (21): 1639.

https://doi.org/10.1182/blood.V122.21.1639.1639

Published: 2013

Journal Articles

Inherited genetic susceptibility to monoclonal B-cell lymphocytosis

Dalemari Crowther-Swanepoel, Tanguy Corre, Amy Lloyd, Gianluca Gaidano, Bianca Olver, Fiona L. Bennett, Chi Doughty, Daniela Toniolo, Federico Caligaris-Cappio, Paolo Ghia, Davide Rossi, Andy C. Rawstron, Daniel Catovsky, Richard S. Houlston

Blood (2010) 116 (26): 5957–5960.

https://doi.org/10.1182/blood-2010-07-294975

Published: 2010

Journal Articles

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

Andy C Rawstron, PhD, Chi Doughty, PhD, Ruth M de Tute, Fiona Bennett, Selina Denman, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Andrew Jack, PhD, MB

Blood (2010) 116 (21): 2002.

https://doi.org/10.1182/blood.V116.21.2002.2002

Published: 2010

NARROW

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Minimal residual disease is an independent predictor for 10-year survival in CLL

Validation of Plasma Cell Immunophenotype As a Biomarker to Identify High-Risk Smoldering Myeloma

Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Iciclle Extension Study

Novel Targeted Therapies and Their Impact on Survival from Multiple Myeloma (MM) and Chronic Lymphocytic Leukaemia (CLL) in the Real World

Impact of Minimal Residual Disease in Transplant Ineligible Myeloma Patients: Results from the UK NCRI Myeloma XI Trial

Compartment Effect on the Prognostic Significance of MRD Detection in CLL: Impact of Treatment Type and Duration of Follow-up

B-Cell Lymphopenia and Circulating Neoplastic B-Cell Populations Are Associated with High Risk Disease in DLBCL: Results from the UK Remodl-B Trial

Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project

The Level of Residual CLL Objectively Predicts the Outcome of Patients Following FCR-Based Therapy with Sequential Benefits per Log Depletion and Improved Post-Treatment Monitoring

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction

Variable Expression of Therapeutic Antibody Targets May Have Implications for Efficacy of Therapy in Myeloma and Waldenstrom Macroglobulinaemia

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Patients With DLBCL Commonly Have B-Cell Lymphopenia and Circulating Clonal B-Cell Populations With a Phenotype Concordant With The Underlying Tumour

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Inherited genetic susceptibility to monoclonal B-cell lymphocytosis

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only